Shared on 28 Oct 25
Fair value Decreased 32%Karyopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.
Shared on 13 Oct 25
Fair value Decreased 11%Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.
Shared on 15 Aug 25
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.
Shared on 01 May 25
Fair value Decreased 42%Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Shared on 24 Apr 25
Fair value Increased 54%Phase III SENTRY And XPOVIO Approvals Will Secure Future Success
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 1.10%